Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer

A Clinical Trial to Develop a Peritoneal Carcinomatosis Index (PCI) in Ovarian

• Primary objectives: To develop peritoneal carcinomatosis index (PCI) for ovarian cancer, tubal cancer and primary peritoneal cancer that can represent perioperative intraperitoneal tumor burden objectively
• Secondary objectives: To establish the relationship and find out clinical significance between PCI, tumor location and tumor characteristics

Patients with primary ovarian cancer

• Informed consent

• Digital photography & Checking PCI (tumor size, number, and Characteristics)

• Postoperative surveillance(tumor marker, image and physical examination)

  1. Developing the best fitting PCI model to reflect recurrence-free survival and overall survival

     • Selection of items
     • Weighting by items and tumor characteristics

  2. Analysis of prognostic impact of PCI compared to conventional staging system (FIGO stage) for ovarian cancer

Inclusion Criteria:

1. Preoperative clinical diagnosis of ovarian cancer, tubal cancer, and primary peritoneal carcinoma (all stage)
2. Available preoperative image study (CT and/or MRI and/or PET)
3. Patients who gave a written informed consent
4. Patients must be surgical candidate considering medical and psychological condition

Exclusion Criteria:

• Patients who refuse to participate or want to withdraw at anytime.